Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 18/20 | 0.57 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20249516 | 1.00 | VNN1 (0.57) | VNN1L3MBTL3HRH3 | |
| SCHEMBL20249503 | 0.93 | L3MBTL3 (0.65) | VNN1L3MBTL3 | |
| SCHEMBL5909079 | 0.90 | L3MBTL3 (0.55) | VNN1L3MBTL3HRH3 | |
| SCHEMBL5909268 | 0.84 | L3MBTL3 (0.58) | VNN1L3MBTL3HRH3 | |
| SCHEMBL5908969 | 0.84 | L3MBTL3 (0.58) | VNN1L3MBTL3HRH3 | |
| SCHEMBL12776429 | 0.84 | VNN1 (0.47) | VNN1L3MBTL3 | |
| SCHEMBL24185771 | 0.82 | L3MBTL3 (0.57) | VNN1L3MBTL3HRH3 | |
| SCHEMBL20037662 | 0.82 | L3MBTL3 (0.57) | VNN1L3MBTL3HRH3 | |
| SCHEMBL22164612 | 0.82 | L3MBTL3 (0.57) | VNN1L3MBTL3HRH3 | |
| SCHEMBL20037660 | 0.82 | L3MBTL3 (0.57) | VNN1L3MBTL3HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | VNN1 3630/4885L3MBTL3 4221/4885HRH3 2304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.